Apollo Biowellness, Inc. Announces Exclusive Distribution Deal
Apollo Biowellness (OTC Pink: KOAN) has secured an exclusive distribution agreement with Revive Regenerative, Inc. for its subsidiary Evolutionary Biologics' "Evo Bio" brand products across the United States and Canada. The distribution network includes plastic surgeons, dermatologists, med spas, and other healthcare providers.
The company anticipates significant growth in the last two quarters of 2025 and throughout 2026 as a result of this partnership. Apollo Biowellness also plans to pursue additional distribution agreements in Europe, Asia, and South America. This strategic move will allow Evolutionary Biologics to focus on developing new products and brands.
Revive Regenerative, recognized as a leader in the regenerative laser field, serves as an integrated supply chain provider for biologics and energy-based laser aesthetics, with a consumer products division established through strategic mergers and acquisitions.
Apollo Biowellness (OTC Pink: KOAN) ha ottenuto un accordo esclusivo di distribuzione con Revive Regenerative, Inc. per i prodotti del marchio "Evo Bio" della sua controllata Evolutionary Biologics negli Stati Uniti e in Canada. La rete di distribuzione comprende chirurghi plastici, dermatologi, centri medici estetici e altri operatori sanitari.
L'azienda prevede una crescita significativa negli ultimi due trimestri del 2025 e per tutto il 2026 grazie a questa collaborazione. Apollo Biowellness intende inoltre cercare ulteriori accordi di distribuzione in Europa, Asia e Sud America. Questa mossa strategica permetterà a Evolutionary Biologics di concentrarsi sullo sviluppo di nuovi prodotti e marchi.
Revive Regenerative, riconosciuta come leader nel campo dei laser rigenerativi, opera come fornitore integrato della catena di approvvigionamento per prodotti biologici e laser estetici basati sull’energia, con una divisione di prodotti per il consumatore creata tramite fusioni e acquisizioni strategiche.
Apollo Biowellness (OTC Pink: KOAN) ha asegurado un acuerdo exclusivo de distribución con Revive Regenerative, Inc. para los productos de la marca "Evo Bio" de su subsidiaria Evolutionary Biologics en Estados Unidos y Canadá. La red de distribución incluye cirujanos plásticos, dermatólogos, spas médicos y otros proveedores de salud.
La compañía anticipa un crecimiento significativo en los últimos dos trimestres de 2025 y a lo largo de 2026 gracias a esta asociación. Apollo Biowellness también planea buscar acuerdos adicionales de distribución en Europa, Asia y Sudamérica. Este movimiento estratégico permitirá a Evolutionary Biologics enfocarse en desarrollar nuevos productos y marcas.
Revive Regenerative, reconocida como líder en el campo de los láseres regenerativos, actúa como proveedor integrado de la cadena de suministro para biológicos y estética láser basada en energía, con una división de productos para consumidores establecida a través de fusiones y adquisiciones estratégicas.
Apollo Biowellness (OTC Pink: KOAN)은 자회사 Evolutionary Biologics의 "Evo Bio" 브랜드 제품에 대해 Revive Regenerative, Inc.와 미국 및 캐나다 전역에 대한 독점 유통 계약을 체결했습니다. 유통 네트워크에는 성형외과 의사, 피부과 의사, 메디스파 및 기타 의료 제공자가 포함됩니다.
회사는 이 파트너십을 통해 2025년 하반기와 2026년 전반기에 상당한 성장을 기대하고 있습니다. 또한 Apollo Biowellness는 유럽, 아시아, 남미에서 추가 유통 계약을 추진할 계획입니다. 이 전략적 조치는 Evolutionary Biologics가 신제품 및 브랜드 개발에 집중할 수 있도록 합니다.
재생 레이저 분야의 선두주자로 인정받는 Revive Regenerative는 생물학적 제품과 에너지 기반 레이저 미용 제품을 위한 통합 공급망 제공업체로서, 전략적 인수합병을 통해 소비자 제품 부문을 구축했습니다.
Apollo Biowellness (OTC Pink : KOAN) a conclu un accord exclusif de distribution avec Revive Regenerative, Inc. pour les produits de la marque "Evo Bio" de sa filiale Evolutionary Biologics aux États-Unis et au Canada. Le réseau de distribution comprend des chirurgiens plasticiens, des dermatologues, des spas médicaux et d'autres prestataires de soins de santé.
L'entreprise prévoit une croissance significative au cours des deux derniers trimestres de 2025 et tout au long de 2026 grâce à ce partenariat. Apollo Biowellness envisage également de rechercher des accords de distribution supplémentaires en Europe, en Asie et en Amérique du Sud. Cette démarche stratégique permettra à Evolutionary Biologics de se concentrer sur le développement de nouveaux produits et marques.
Reconnu comme un leader dans le domaine des lasers régénératifs, Revive Regenerative agit en tant que fournisseur intégré de la chaîne d'approvisionnement pour les produits biologiques et l'esthétique laser à base d'énergie, avec une division produits grand public créée par le biais de fusions et acquisitions stratégiques.
Apollo Biowellness (OTC Pink: KOAN) hat eine exklusive Vertriebsvereinbarung mit Revive Regenerative, Inc. für die "Evo Bio"-Markenprodukte seiner Tochtergesellschaft Evolutionary Biologics in den USA und Kanada abgeschlossen. Das Vertriebsnetz umfasst plastische Chirurgen, Dermatologen, Med Spas und andere Gesundheitsdienstleister.
Das Unternehmen erwartet aufgrund dieser Partnerschaft ein signifikantes Wachstum in den letzten beiden Quartalen 2025 und im gesamten Jahr 2026. Apollo Biowellness plant außerdem, weitere Vertriebsvereinbarungen in Europa, Asien und Südamerika anzustreben. Dieser strategische Schritt ermöglicht es Evolutionary Biologics, sich auf die Entwicklung neuer Produkte und Marken zu konzentrieren.
Revive Regenerative, anerkannt als führend im Bereich regenerativer Laser, fungiert als integrierter Lieferkettenanbieter für Biologika und energie-basierte Laserästhetik und verfügt über eine Verbrauchersparte, die durch strategische Fusionen und Übernahmen aufgebaut wurde.
- Secured exclusive distribution agreement for US and Canada markets
- Access to established network of medical professionals and facilities
- Company projects significant growth for Q3-Q4 2025 and 2026
- Strategic focus enabled for new product development
- Potential for additional international distribution agreements
- No specific revenue projections or financial terms disclosed
- Success dependent on distributor's performance
North Bergen, New Jersey--(Newsfile Corp. - July 1, 2025) - Apollo Biowellness, Inc. (OTC Pink: KOAN) (the "Company") announces that it has entered into an exclusive distribution sales agreement with Revive Regenerative, Inc., covering the United States and Canada for the distribution of its subsidiary Evolutionary Biologics products; the "Evo Bio" Brand. Revive Regenerative has distribution channels with Plastic Surgeons, Dermatologists, Med Spas and other providers. With the distribution agreement we expect significant growth for the last two quarters of 2025 and further significant growth in 2026.
Evolutionary Biologics Ad Campaign
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10533/257378_7eeedac234bb1a71_001full.jpg
The Company expects to enter into additional distribution agreements for other parts of the world, Europe, Asia, South America, etc. These distribution agreements will allow Evolutionary Biologics to concentrate on the development of additional products and brands.
You can follow and contact the Company on X at @ApolloBioKOAN.
James W. Zimbler, President, stated, "By entering into the exclusive distribution sales agreement with Revive Regenerative, and its experienced marketing and sales teams, we can expand the reach of Evo Bio and also concentrate on the development of exciting new products."
Revive Regenerative, Inc., is a leader in the regenerative laser field, and serves as the integrated supply chain backbone for biologics and energy-based laser aesthetics, and a consumer products division was formed through a series of strategic mergers, acquisitions and joint ventures.
About Apollo Biowellness, Inc.
Apollo Biowellness, Inc., and its subsidiary, Evolutionary Biologics, Inc., is engaged in the discovery, development and marketing of products designed to better mankind. We believe we are positioning our company as a leader in the field of Regenerative Medicine as defined by the National Institute of Health using biologic based products. Intended products are to be marketed under third-party label exemptions. We are focusing our current efforts on marketing licensed patent-pending natural stem cell mobilizing agents capable of enhancing each individual's ability to mobilize their own adult stem cells from their bone marrow. Also, we are licensed under a patent-pending application to market a dual acting all-natural diet aid designed to help control hunger through normal body signals to the brain and stomach. Products are being developed for consumer and professional markets.
Before using any of our products, you should always consult with your veterinarian and/or family doctor.
Forward-Looking Statements
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to our ability to raise capital, the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. A complete discussion of the risks and uncertainties that may affect the Company's business, including the business of any of its subsidiaries, is included in "Risk Factors" in the Company's most recent Annual Report on Form 10-K as filed by the Company with the Securities and Exchange Commission.
Corporate Contact
James W. Zimbler
President/CEO/Director
info@evolutionarybiologics.com
https://evobiologics.com/
631-806-1420
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/257378
FAQ
What is the new distribution agreement announced by Apollo Biowellness (KOAN)?
Which markets will the KOAN distribution agreement cover?
What is the expected impact of the distribution deal on Apollo Biowellness (KOAN)?
Who are the target customers for Apollo Biowellness's Evo Bio products?
What is Revive Regenerative's role in the KOAN distribution agreement?
